

SANGAMO BIOSCIENCES INC  
Form 8-K  
July 21, 2004

**UNITED STATES  
SECURITIES AND EXCHANGE COMMISSION**

Washington, D.C. 20549

**FORM 8-K**

**CURRENT REPORT**

**Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934**

Date of Report (Date of earliest event reported): **July 21, 2004**

**SANGAMO BIOSCIENCES, INC.**

(Exact name of Registrant as specified in its charter)

**Delaware**

(State or other  
jurisdiction)

**000-30171**

(Commission  
File Number  
of incorporation)

**68-0359556**

(I.R.S. Employer  
Identification No.)

**501 Canal Blvd., Suite A100  
Richmond, California 94804**  
(Address of principal executive offices)

**(510) 970-6000**  
(Registrant's telephone number, including area code)

ITEM 7. EXHIBITS

(c) Exhibits

99.1 Press Release of Sangamo BioSciences, Inc. dated July 21, 2004 reporting Sangamo BioSciences, Inc.'s financial results for the quarter ended June 30, 2004.

ITEM 12. RESULTS OF OPERATIONS AND FINANCIAL CONDITION

The information in this Item 12 is being furnished and shall not be deemed filed for the purposes of Section 18 of the Securities Exchange Act of 1934, as amended, or otherwise subject to the liabilities of that Section. The information in this Item 12 shall not be incorporated by reference into any registration statement or other document pursuant to the Securities Act of 1933, as amended.

On July 21, 2004, Sangamo BioSciences, Inc. issued a press release announcing its financial results for the quarter ended June 30, 2004. A copy of the press release is attached as Exhibit 99.1.

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the Registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

DATE: July 21, 2004

SANGAMO BIOSCIENCES, INC.

By: /s/ EDWARD O. LANPHIER II  
Edward O. Lanphier II  
President, Chief Executive Officer

Exhibit Index

<b>Exhibit No.</b>	<b>Description</b>
99.1	Press Release of Sangamo BioSciences, Inc. dated July 21, 2004 reporting Sangamo BioSciences, Inc. s financial results for the quarter ended June 30, 2004.